Marc Unterman, MD
Cardiovascular Disease · Lawrenceville, GANPI 1427044858
Payments from drug & device makers
Across 283 payments — averaging $143.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Pfizer$5K
- Medtronic$3K
- Abbott$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$520
- Edwards Lifesciences$444
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$30,61876%
- Travel & lodging$2,8597%
- Food & beverage$6,94017%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 61 | $26,925 |
| Pfizer | 16 | $5,312 |
| Medtronic(2 entities) | 24 | $2,644 |
| Abbott | 15 | $1,875 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 44 | $520 |
| Edwards Lifesciences | 9 | $444 |
| Merck | 20 | $349 |
| E.r. Squibb & Sons, L.L.C. | 13 | $289 |
| Johnson & Johnson | 15 | $241 |
| Novartis | 12 | $241 |
| Philips North America LLC | 3 | $222 |
| Heartflow, Inc. | 3 | $220 |
| Cvrx, Inc. | 1 | $206 |
| Boston Scientific | 7 | $160 |
| Novo Nordisk | 8 | $156 |
| Bayer | 5 | $122 |
| Boehringer Ingelheim | 6 | $115 |
| Scpharmaceuticals Inc. | 2 | $63 |
| Astellas Pharma US Inc | 1 | $55 |
| AstraZeneca | 3 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Cardiovascular Systems Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| GSK | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$26,123
- ELIQUIS$5,050
- Resolute$1,960
- Omnilink Elite vascular stent system$1,313
- Barostim Neo System$206
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$159
- Micra$159
- SAPIEN 3 Ultra RESILIA$151
- Azurion 7 M20$119
- FFRct$111
How this compares
$40,472 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 943 | $1,130,417 |
| XareltoRivaroxaban | 195 | $219,038 |
| EntrestoSacubitril/Valsartan | 148 | $206,232 |
| Repatha SureclickEvolocumab | 97 | $134,126 |
| JardianceEmpagliflozin | 82 | $116,824 |
| FarxigaDapagliflozin Propanediol | 17 | $20,659 |
| BrilintaTicagrelor | 19 | $16,848 |
| Ranolazine ErRanolazine | 90 | $10,098 |
| Metoprolol Succinate | 657 | $8,153 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 22 | $7,774 |
| CrestorRosuvastatin Calcium | 11 | $7,624 |
| Atorvastatin Calcium | 722 | $6,375 |
| Carvedilol | 620 | $5,363 |
| Losartan Potassium | 587 | $4,981 |
| Metoprolol Tartrate | 663 | $4,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,312 | $1,130,417943 claims |
| Johnson & JohnsonXarelto | $241 | $219,038195 claims |
| NovartisEntresto | $241 | $206,232148 claims |
| Boehringer IngelheimJardiance | $115 | $116,82482 claims |
| AstraZenecaFarxiga, Brilinta, Crestor | $51 | $45,13147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Lawrenceville
- Alexis OkohLawrenceville$65K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.